Appendix 4C – Q3 FY25 Quarterly Cash Flow Report
Globenewswire·2025-04-30 11:35
Highlights Reported positive topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy (MSA) led by robust clinical efficacyPhase 2 data featured in an oral presentation at the American Academy of Neurology Annual MeetingATH434-202 open-label trial in advanced MSA completed in March 2025Cash balance on 31 March 2025 of A$17.96M with an additional A$27.1M raised subsequent to the end of the quarter MELBOURNE, Australia and SAN FRANCISCO, April 30, 2025 (GLOBE NEWS ...